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First case report of a successfully managed severe 
COVID-19 infection in Malawi
Case Report
Presentation of the case
The coronavirus disease 2019 (COVID-19) pandemic is 
now established on the African continent, with cases rapidly 
increasing in Malawi (1742 confirmed cases and 19 deaths as 
of  5 July 20201). Clinicians require guidelines, deliverable in 
the Malawi context, to effectively and safely treat patients for 
the best possible outcome. In Malawi, key public messages 
around social distancing, hand washing and shielding 
for at-risk individuals have been widely distributed by the 
Ministry of  Health. However, it has not been possible to 
implement strict lockdown measures in Malawi due to the 
risk of  widespread economic disruption, hunger, worsened 
food insecurity, risk of  violence and mass political rallies2. 
Testing rates are low such that the number of  confirmed 
cases in Malawi is likely to significantly under-represent 
the actual number of  cases. As the epidemic unfolds, it is 
vital that doctors implement standardised case management 
guidelines to improve survival for patients who require 
hospital admission. The majority of  patients hospitalised 
with COVID-19 require medical-ward level care, including 
provision of  adequate oxygen3. Increased oxygen provision 
has been a major focus of  COVID-19 preparedness activities 
in Malawi4.
We report a case of  a 46-year-old male who was admitted 
to Queen Elizabeth Central Hospital on 17 June 2020, 
complaining of  exertional dyspnoea after a 10-day history 
of  dry cough and fevers. Patient consent was obtained 
for this case report. Other than obesity, he had no other 
significant medical problems and was HIV seronegative. He 
was a lifelong non-smoker and consumed 30–40 units of  
alcohol per week. Shortness of  breath had appeared over a 
period of  2 days accompanied by pleuritic chest pain upon 
coughing. There was no recent foreign travel or contact 
with COVID-19 suspects. He was strongly suspected of  
COVID-19 disease due to reported symptoms of  fever, dry 
cough and worsening shortness of  breath and was admitted 
directly to a hospital ward specifically created for the isolation 
and treatment of  such patients.
Staff  received the patient wearing appropriate personal 
protective equipment (PPE: gloves, gown, visor and N95 
mask) in line with international guidance5. He was transported 
into an isolation ward in the hospital by a family member 
and walked into the bespoke high dependency area. This 
ward was designed specifically for COVID-19 care delivery 
including PPE donning and doffing areas and infection 
control and prevention movement and cleaning measures. 
Negative pressure facilities were not available. Subsequently, 
family members were not permitted to visit the patient. This 
area included provision of  piped oxygen and continuous 
monitoring equipment. The patient was clearly dyspnoeic 
upon arrival with a respiratory rate of  30 breaths/min and 
unable to speak in full sentences; accessory muscle use was 
not observed. His oxygen saturations were immediately 
measured in advance of  further medical history and 
examination and demonstrated SpO2 of  68% and heart rate 
(HR) 110 beats/min (bpm) without supplemental oxygen. 
The patient was immediately treated with oxygen (15 L non-
rebreather reservoir bag FiO2 ~0.6) with improvement in 
SpO2 to 92% and HR 98 bpm. The patient had a normal 
blood pressure, 138/86 mmHg. The patient was orientated 
in time and place and did not demonstrate signs of  confusion 
during the admission. The patient was afebrile but reported 
subjective fevers prior to admission.
Discussion of the case
Doctors applied context-specific medical guidelines based on 
the most up-to-date evidence. Ward rounds and subsequent 
care were delivered with appropriate PPE provided to 
staff. The patient was treated with 6 mg intravenous (IV) 
dexamethasone once daily (OD)6 for 10 days, prophylactic 
subcutaneous low molecular weight heparin (enoxaparin 
60 mg OD)7 and empirical antibiotics (ceftriaxone 2 g OD) 
because it was not possible to exclude a co-existing bacterial 
pneumonia. Antibiotic prescription was in line with World 
Health Organization (WHO) guidance for severe cases 
of  confirmed COVID-198. Antibiotics were discontinued 
after 7 days. Doctors assessed the patient as euvolaemic at 
presentation, and throughout his admission the patient was 
able to eat and drink independently and renal function was 
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normal such that IV fluids were not prescribed and he was 
not catheterised. Initial chest X-ray (Figure 1A) demonstrated 
diffuse ground glass opacities and consolidations in keeping 
with COVID-19 pneumonia9. A reverse transcriptase 
polymerase chain reaction (RT-qPCR) test for severe acute 
respiratory syndrome coronavirus 2 (SARS CoV-2) the 
following morning confirmed COVID-19 diagnosis with 
probable high viral load (CT N1 26.0, N2 26.4 and RP 25). 
This test screens for the nucleocapside (N)-gene of  SARS-
CoV-2 cycle threshold (CT) and also human ribonuclease 
protein (RP) as an internal control to assess extraction quality. 
Results were reported to statutory national and local bodies 
in line with Malawi Ministry of  Health guidance and contact 
tracing initiated by the local District Health Office. A SARS 
CoV-2 serology test was strongly positive with an optical 
density of  3.5 (5 times above cut-off  value of  seropositivity). 
The full blood count results (Table 1) showed typical severe 
COVID-19 profile10, a neutrophil-to-lymphocyte ratio 
(NLR) of  5.4 at 2 days post admission to hospital. An NLR 
of  greater than 4 at admission is associated with more severe 
outcome and is a predictor of  admission to the intensive 
care unit (ICU)11. The patient remained hypoxic for 4 days, 
requiring 15 L oxygen to maintain SpO2 at 88–92% but 
subjectively began to feel better. During this time the patient 
continued to receive prescribed medications and received 
high-quality nursing care from staff  trained specifically to 
treat COVID-19 patients. This included chest physiotherapy 
manoeuvres, including deep breathing exercises (wearing a 
mask to reduce aerosols) and encouragement of  self-proning 
according to UK Intensive Care Society Guidelines12. The 
patient tolerated self-proning well and was able to remain 
in prescribed positions for up to 2 hours at a time, in line 
with guideline recommendations. Staff  observed that 
oxygen saturations improved upon proning by 2–3%. On 
day four the SpO2 worsened to 86% and the respiratory rate 
increased. Treatment dose of  enoxaparin (60 mg twice daily) 
was empirically commenced (gold standard CT pulmonary 
angiography not possible) for presumptive pulmonary 
embolism. Plans for continuous positive airways pressure 
support and mechanical ventilation were prospectively 
discussed with the anaesthetic team but these modalities of  
care were not indicated during the clinical course.
The following day gas exchange had improved so oxygen 
was titrated to 10 L to achieve SpO2 94–96%, and the NLR 
had reduced to 4.5 (Table 1). The enoxaparin was reduced to 
a prophylaxis dose (40 mg OD) after clinical improvement 
was seen over 48 hours, in consideration of  the long-term 
risk–benefit, given that a diagnosis of  pulmonary embolism 
could not be confirmed.  Subsequently, oxygen was titrated 
to no supplemental oxygen over the following week and 
the patient was discharged from hospital 10 days after 
admission (discharge saturation 91%). Discharge chest X-ray 
demonstrated partial resolution of  findings (Figure 1B). The 
patient was advised to complete a period of  self-isolation at 
home for 10 days after symptom onset plus at least 3 days 
without symptoms in line with WHO recommendations8, 
with ongoing pulmonary rehabilitation (telemedicine 
physiotherapy advice). 
We present this case report as an example of  successful 
management using standardised, evidence-based treatment 
guidelines to inform the future management of  patients 
in the Malawi context. Successful management of  severe 
hypoxic COVID-19 disease includes oxygen titrated to SpO2, 
self-proning to improve lung perfusion, dexamethasone 
(if  not contraindicated), access to heparin and effective 
multidisciplinary teamwork.
ALT, alanine aminotransferase; AST, aspartate 
aminotransferase; GGT, gamma-glutamyltransferase; MCV, 
mean corpuscular volume; WBC, white blood cell count.
Figure 1. Paired chest X-ray findings on day 2 (A) and day 13 (B) 
in a patient admitted to hospital with severe COVID-19 infection. 
X-rays demonstrate diffuse bilateral alveolar shadowing and an 
incidental hiatus hernia.
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